对比菊池病与菊池病合并自身免疫疾病18F-FDG PET/CT表现

目的 对比单纯菊池病(KFD)与KFD合并自身免疫疾病病灶代谢活性的差异。方法 将18例经病理证实为KFD且接受¹⁸F-FDG PET/CT检查患者，分为单纯KFD组(n=9)及KFD合并自身免疫疾病组(n=9),观察KFD全身累及情况，比较组间临床资料、实验室检查及病灶代谢参数的差异。结果 组间患者临床资料及实验室检查差异均无统计学意义(P均>0.05)。PET/CT显示KFD患者存在全身多处淋巴结异常，如颈部、腋窝、纵隔、脾门、腹膜后、髂血管旁及腹股沟，亦可累及骨髓和脾脏。组间淋巴结受累部位、FDG摄取最高淋巴结位置及伴脾脏增大比例差异均无统计学意义(P均>0.05)。KFD合并自身免疫疾病组受累淋巴结肿瘤代谢体积(MTV)_40%及病灶糖酵解总量(TLG)_40%、脾脏平均标准摄取值(SUV)、骨髓最大SUV均高于单纯KFD组(P均<0.05)。结论 合并自身免疫疾病的KFD患者与单纯KFD患者之间，受累淋巴结、脾脏及骨髓代谢参数均存在差异。     

Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography evaluation of subcutaneous panniculitis-like T cell lymphoma and treatment response

Subcutaneous panniculitis-like T cell lymphoma (SPTCL) is a very rare variant of non-Hodgkin’s lymphoma. Currently, there is no standard imaging method for staging of SPTCL nor for assessment of treatment response. Here, we describe our use of fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for staging and monitoring of treatment response in 3 cases of SPTCL. Primary staging by PET/CT showed that all 3 patients had multiple foci in the subcutaneous fat tissue, with SUVmax from 10.5 to 14.6. Involvement of intra-abdominal fat with high SUVmax was identified in 2 of the patients. Use of the triple drug regimen of gemcitabine, cisplatin and methylprednisolone (commonly known as “GEM-P”) as first-line therapy or second-line therapy facilitated complete metabolic response for all 3 cases. FDG PET/CT provides valuable information for staging and monitoring of treatment response and can reveal occult involvement of the intra-abdominal visceral fat. High FDG uptake on pre-treatment PET can identify patients with aggressive disease and help in selection of first-line therapy.     

18F-FDG PET/CT在肾脏肿瘤诊疗中的应用

目的评价18F-FDG PET/CT在肾脏肿瘤诊断和治疗中的价值。方法对30例CT或MRI确诊或怀疑肾脏肿瘤的患者行18F-FDG PET/CT显像,22例患者行延迟显像。所有肾脏肿瘤均经手术或穿刺活检后病理确诊。评价18F-FDG PET/CT对患者治疗方案的影响。结果 30例中,肾细胞癌(RCC)24例,肾神经内分泌肿瘤1例,淋巴瘤3例,肺癌肾转移1例,肾脏炎性病变1例。PET/CT诊断肾脏肿瘤的灵敏度为89.66%(26/29),特异度为100%(1/1),准确率为90.00%(27/30),阳性预测值为100%(26/26),阴性预测值为25.00%(1/4)。PET/CT检出肾癌伴肾门淋巴结转移2例,远处转移5例。8例(RCC 4例、肾淋巴瘤3例及肾转移癌1例)接受PET/CT后治疗方案发生改变。显像阳性肾癌患者Fuhrman分级高于阴性患者(P<0.05),显像阳性肾癌平均直径大于阴性者(P<0.05)。22例肾癌早期最大标准摄取(SUVmax)值与延迟显像SUVmax值差异无统计学意义(P>0.05)。结论 18F-FDG PET/CT可准确显示肾肿瘤患者局部病变及远处转移。对可疑肾淋巴瘤及肾转移瘤患者应行18F-FDG PET/CT显像,以明确分期并寻找原发灶。     

罗萨伊-多尔夫曼病18F-FDG PET/CT表现

目的 观察罗萨伊-多尔夫曼病(RDD)¹⁸F-FDG PET/CT表现。方法 纳入6例活检病理确诊RDD患者，分析其¹⁸F-FDG PET/CT及其他常规影像学检查资料，观察RDD ¹⁸F-FDG PET/CT表现特点。结果 本组6例RDD中，1例为皮肤原发病变，3例为淋巴结内+结外病变，2例仅有淋巴结内病变；最常见的结外受累部位为骨(n=3),其次为鼻咽/鼻腔及鼻窦(n=2);PET/CT示其均呈FDG高摄取，最大标准摄取值为4.3～16.5。结论 RDD病灶¹⁸F-FDG PET/CT表现为FDG高摄取。     

F-18 fluorodeoxyglucose positron emission tomography/computed tomography image of gastric mucormycosis mimicking advanced gastric cancer: A case report

BACKGROUND Mucormycosis is a very rare fungal infection,and its prognosis is poor.Most common sites of infection are the sinuses,lung,or skin,and gastric involvement is uncommon.The standard antifungal therapy is the treatment of choice for gastric mucormycosis.However,the symptoms of gastric mucormycosis are varied and the early diagnosis is not easy.CASE SUMMARY I report a 53-year-old alcoholic man,who was admitted due to epigastric pain.The upper gastrointestinal endoscopy revealed a huge ulcer lesion in the stomach,which was suspected to be gastric cancer.F-18 fluorodeoxyglucose positron emission tomography/computed tomography(F-18 FDG PET/CT)showed diffusely intense FDG uptake at the ulcer lesion of the stomach,and several enlarged hypermetabolic lymph nodes were noted at the left gastric chain.Although,endoscopy and F-18 FDG PET/CT findings suggested advanced gastric cancer with regional lymph node metastases,there was no cancer cells in the biopsy results and multiple fungal hyphae were noted in the periodic acid-Schiff stained image.CONCLUSION He was diagnosed with gastric mucormycosis and successfully underwent amphotericin B and posaconazole treatment.     

Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: PET/CT

Nodal involvement of abdominal lymphatic pathways occurs in a number of histologic subtypes of malignant lymphoma. The histologic diagnosis of abnormal uptake in abdominal lymphatic pathways includes mainly non-Hodgkin lymphoma with B-cell lineage and Hodgkin lymphoma. Initial involvement of pelvic and retroperitoneal lymphatic pathways can result from a variety of underlying non-Hodgkin’s lymphoma: follicular lymphoma, diffuse large B-cell lymphoma, marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type, and mantle cell lymphoma. The diagnosis of these clinical entities requires various imaging techniques, including fluorine-18-fluorodeoxyglucose (¹⁸FDG) positron emission tomography/computed tomography (PET/CT), computed tomography, ⁶⁷Gallium scintigraphy, and magnetic resonance imaging (MRI). Specific symptoms of these diseases are often lacking, but intense ¹⁸FDG accumulation on PET/CT may be a marker of disease activity. Interpretation of the presence of and the specific pattern of ¹⁸FDG uptake may obviate the need for invasive biopsy. However, distinction of abnormal uptake is often difficult to determine because focal accumulation of ¹⁸FDG in the urinary tract or intestine mimics nodal involvement in the pelvic and retroperitoneal lymphatic pathways. In this review, specific conditions causing nodal involvement of pelvic and retroperitoneal lymphatic pathways in patients with malignant lymphoma that may impact diagnostic and treatment decisions are highlighted.     

Expression of glucose transporter-1, hypoxia-inducible factor-1α, phosphatidylinositol 3-kinase and protein kinase B (Akt) in relation to [(18)F]fluorodeoxyglucose uptake in nasopharyngeal diffuse large B-cell lymphoma: a case report and literature review

This report presents a case of nasopharyngeal diffuse large B-cell lymphoma and a literature review concerning the use of [(18)F]fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). A 37-year old man was admitted to hospital complaining of nasal secretions with minor epistaxis and a 20-year history of snoring. Nasal endoscopy found diffuse swelling in the nasopharynx and a biopsy was performed. Prior to chemotherapy, FDG-PET/CT showed soft tissue diffuse thickening and FDG accumulation in the nasopharynx and bilateral cervical lymph nodes; FDG did not accumulate elsewhere. After four cycles of chemotherapy (rituximab, cyclo phosphamide, doxorubicin, vincristine) and prednisone treatment, FDG-PET/CT showed that FDG still accumulated in the nasopharynx and bilateral cervical lymph nodes, therefore radiotherapy was initiated. At 1 year, FDG-PET/CT showed no FDG accumulation. Immunohistochemical analysis revealed that the tumour was positive for phosphorylated protein kinase B (Akt), suggesting that FDG uptake may be associated with factors activated by the phosphatidylinositol 3-kinase/Akt signalling pathway.     

18F-FDG PET/CT在乳腺外Paget病分期及随访中的应用(附11例报道)

目的 探讨¹⁸F-FDG PET/CT在乳腺外Paget病的分期及治疗后随访中的临床应用价值。方法 回顾性分析11例经手术或活检病理证实的乳腺外Paget病患者临床及影像学检查资料。结果 11例患者中,7例术前接受¹⁸F-FDG PET/CT检查,4例术后接受¹⁸F-FDG PET/CT检查。10例检查时存在皮肤病变,1例无皮肤病变;9例病灶位于阴囊,2例病灶位于腋窝。皮肤病灶¹⁸F-FDG PET/CT均表现为轻、中度摄取增高。5例患者伴有腹股沟淋巴结转移(5/11,45.45%)。2例既往有其他恶性肿瘤病史的患者均未见肿瘤复发征象;1例阴囊Paget病手术切除后1年局部复发患者,¹⁸F-FDG PET/CT发现升结肠肿物,伴肝脏、骨骼及淋巴结多发转移。结论 ¹⁸F-FDG PET/CT有助于乳腺外Paget病的术前分期,并可用于临床随访。     

FDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma

This comprehensive case series illustrates the findings on 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) of patients with varying stages of cutaneous T-cell lymphoma (CTCL). Patients were imaged with full-body scanning using a General Electric Discovery ST 16-slice PET/CT machine. Patients were assessed by PET/CT for cutaneous, nodal, and solid organ FDG uptake, indicative of highly metabolically active (i.e., putatively malignant cells) disease, and comparisons were made to CT data alone and to the physical examination. Several key observations strongly suggested that information afforded by PET/CT scan may be valuable. Various cutaneous lesions, from thin subtle plaques to thick tumors, were revealed and corresponded accurately to the cutaneous examination. In the case of subcutaneous lesions, PET/CT outperformed physical exam. CT also provided the depth/thickness of lesions. The differing levels of FDG uptake in enlarged nodes found within an individual patient as well as among different patients may potentially distinguish reactive from malignant adenopathy. Additionally, lymph nodes that did not meet staging size criteria (e.g., were not > 1 cm) revealed increased metabolic activity and, therefore, could be targeted for subsequent monitoring or biopsy. In addition, PET/CT identified visceral involvement in cases with advanced disease. In summary, PET/CT can provide physiologic and anatomic information on the wide diversity of external and internal lesions in CTCL and, therefore, may have great potential for improving the staging and monitoring of response to therapy of cutaneous, nodal, and visceral disease.     

Pretreatment with Diphenoxylate Hydrochloride/Atropine Sulfate (Lomotil) does not Decrease Physiologic Bowel FDG Activity on PET/CT Scans of the Abdomen and Pelvis

Purpose  Physiologic uptake of 2-[¹⁸F]-fluoro-2-deoxy-d-glucose (FDG) by bowel can confound positron emission tomography/computed tomography (PET/CT) assessment for abdominal pathology, particularly within the bowel itself. We wished to determine if oral administration of the antimotility agent, Lomotil (5 mg diphenoxylate hydrochloride/0.05 mg atropine sulfate; G.D. Searle and Company, a division of Pfizer), prior to PET/CT scanning would reduce physiologic uptake of FDG by the small bowel and colon (lower gastrointestinal [GI] tract). Procedures  Patients undergoing PET/CT scans for lymphoma were enrolled in a prospective, randomized, double-blinded study and received either 10 mL water (control group) or 10 mL Lomotil (experimental group) orally 30–60 min prior to scanning. Scans were reviewed independently by two blinded experienced readers and scored for the degree of FDG activity in the lower GI tract relative to liver activity. Results  The administration of Lomotil prior to PET/CT scanning did not reduce physiologic FDG activity in the small bowel and colon. In contrast, increased radiotracer uptake by the lower GI tract was observed in the Lomotil group compared to the control group. Conclusions  Pretreatment with Lomotil prior to PET/CT scanning confers no benefit toward the reduction of physiologic FDG uptake by the small bowel and colon.     

组织细胞坏死性淋巴结炎18F-FDG PET/CT表现

目的 观察组织细胞坏死性淋巴结炎（HNL）¹⁸F-FDG PET/CT表现。方法 回顾性分析11例经病理证实HNL患者的¹⁸F-FDG PET/CT及临床表现,分区域选取¹⁸F-FDG摄取最高的病变淋巴结54枚,分析其最大径、位置与最大标准摄取值（SUV_max）的相关性。结果 11例HNL中,7例受累淋巴结呈全身性分布,4例仅颈部和/或腋窝淋巴结受累;11例颈部淋巴结均受累,9例腋窝淋巴结受累;受累淋巴结呈卵圆形,最大短径均<2.30 cm,密度多均匀,且无融合趋势;¹⁸F-FDG PET/CT显像见不同程度放射性摄取,SUV_max为1.22~23.34,中位SUV_max为5.56（2.37,9.87）。8例发热患者中,6例中轴骨摄取高于肝脏。淋巴结最大短径、最大长径均与SUV_max呈低度正相关（r=0.496,P<0.001;r=0.347,P=0.010）,所在位置与SUV_max无明显相关（r=0.019,P=0.892）。结论 HNL于¹⁸F-FDG PET/CT显像主要表现为全身多发淋巴结轻、中度肿大,颈部及腋窝淋巴结多受累及代谢增高,伴或不伴中轴骨代谢增高。¹⁸F-FDG PET/CT可用于评估HNL患者全身淋巴结受累、判断疾病活动度及辅助活检定位。     

18F-FDG PET/CT显像脾脏弥漫代谢增高原因分析

目的 探讨¹⁸F-FDG PET/CT显像中脾脏摄取弥漫性增高的原因。方法 以脾脏弥漫性摄取高于肝脏为研究纳入标准,脾脏SUV_max/肝脏SUV_max>1为定量指标,共纳入36例患者,结合手术病理、出院诊断及随访结果,分析患者疾病构成情况。结果 36例脾脏摄取弥漫性增高的患者中,15例淋巴瘤、3例结核、9例其他感染性疾病、1例大动脉炎、1例系统性红斑狼疮,1例自身免疫性溶血性贫血,2例特发性血小板减少性紫癜,1例结节病、3例实体肿瘤(其中2例正在接受粒细胞集落刺激因子治疗)。结论 PET/CT显像中脾脏弥漫性代谢增高的现象,在淋巴瘤、结核及其他炎症状态、贫血、结节病、正在接受粒细胞集落刺激因子的患者中均可以出现,并不是某一类疾病的特征性表现。     

Utility of sonographically guided biopsy in metabolically suspected recurrent lymphoma.

OBJECTIVE: The purpose of this study was to determine the diagnostic accuracy of sonographically guided biopsy of [(18)F]fluorodeoxyglucose (FDG)-avid foci on positron emission tomography (PET)/computed tomography (CT) in patients with lymphoma. METHODS: We retrospectively reviewed the medical records of 56 patients with lymphoma (25 male and 31 female; mean age, 48.5 years; range, 22-80 years) who underwent sonographically guided biopsy of hypermetabolic FDG-avid foci precisely localized by PET/CT. Biopsies were performed up to 3 months after PET/CT. The accuracy of core biopsy was calculated and compared with clinical follow-up and histopathologic results of open biopsy. RESULTS: Sixty-six sonographically guided biopsies were performed in the 56 patients. Histopathologic results were conclusive in 53 (80%) of 66. No complications occurred during or after the procedure. The overall sensitivity, specificity, positive predictive value, and accuracy for diagnosis of lymphoma were 100%, 95%, 97%, and 98%, respectively. CONCLUSIONS: Sonographically guided biopsy is a safe and effective means for investigating metabolically active lesions on FDG-PET/CT in patients with known lymphoma.     

比较PET/CT与PET/MRI诊断成人淋巴瘤

目的 比较PET/CT与PET/MRI诊断成人淋巴瘤的效能。方法 前瞻性观察45例淋巴瘤患者，行全身PET/CT和PET/MR检查，分别由2名医师独立评估PET/CT和PET/MRI，获得病灶最大标准摄取值（SUV_max）及对应D值、D^*值和f值，分析两种模式的诊断效能及分期差异。结果 PET/CT与PET/MRI均测出55个淋巴结和5个结外病灶的SUV_max，基于体素内不相干运动（IVIM）模型测出39个病灶的对应值。医师间对阳性病灶检测率一致性极强（k=1.000），PET/CT与PET/MRI的一致性极强（k=0.956）；对于淋巴瘤分期，PET/CT与PET/MRI一致性极强（k=0.965）；PET/CT与PET/MRI的SUV_max呈高度相关（r=0.892，P<0.001），D值与SUV值低度相关（r=-0.312，P<0.050），f值与SUV值呈中度相关（r=0.520，P<0.001）。结论 PET/CT与PET/MRI对成人均有良好诊断效能，PET/MRI可提高淋巴瘤诊断及分期的准确率，多参数联合可预测和评估肿瘤异质性。     

18F-FDG-PET/CT诊断淋巴瘤化疗性肺损伤

目的 探讨¹⁸F-FDG-PET/CT显像诊断淋巴瘤化疗性肺损伤的价值。方法 回顾性分析既往因淋巴瘤化疗评估接受PET/CT检查并发现肺内新发病灶的患者,筛选最终临床诊断为化疗性肺损伤的病例,分析后其临床及影像学特点。结果 共10例患者诊断为化疗性肺损伤。涉及的化疗方案包括4例R-CHOP,2例R-EPOCH,1例BEACOP,1例R-BEACOP,1例R-GDP及1例克拉屈滨。5例患者无明显症状。PET/CT表现：2例患者累及单肺、8例双肺受累。肺内损伤主要为磨玻璃密度影、网格影、斑片影及实变。病变区域最大标准化摄取比值（SUV_max）为1.33~4.83,患者病灶SUV_max/纵隔血池SUV_mean为0.88~4.09。患者接受停药及激素治疗后复查CT,肺内病变均明显好转。结论 ¹⁸F-FDG-PET/CT可早期发现尚未出现临床症状的肺损伤,对诊断淋巴瘤化疗性肺损伤有价值。     

The role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/computed tomography in monitoring the immunosuppressive therapy response of inflammatory myofibroblastic tumor.

PURPOSE: To compare the pre and post treatment 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG)-positron emission tomography (PET)/computed tomography (CT) imaging findings of an inflammatory myofibroblastic tumor (IMT) with its clinical response to immunosuppressive therapy. PROCEDURE: Forty-nine-year-old female presented with dyspnea, chest pain, and weight loss and underwent an FDG-PET/CT scan before and after mediastinal biopsy and treatment with dexamethasone and thalidomide. RESULTS: FDG-PET/CT scan demonstrated a hypermetabolic mediastinal mass. The biopsy of the lesion was consistent with IMT. Following immunosuppressive therapy, the patient's clinical findings resolved, and PET/CT showed a significant decrease in the FDG uptake and the size of the mass. CONCLUSION: Pre-treatment imaging features and post-treatment imaging characteristics of IMT correlate with clinical findings and suggest that FDG-PET/CT may be useful as an adjunct to clinical evaluation in monitoring of immunosuppressive therapy of IMT.     

~(18)F-FDG PET/CT在皮肤淋巴瘤中的初步应用

目的皮肤淋巴瘤是较常见的结外淋巴瘤,本文初步探讨PET/CT在皮肤淋巴瘤中的价值。方法回顾性分析我院近5年来的12例皮肤淋巴瘤患者PET/CT图像,根据治疗情况分为治疗组(A组)及未治疗组(B组),比较皮肤病变与PET/CT结果的关系。结果 A组中6例行PET/CT随访及再分期,其中2例PET/CT显像未见FDG高代谢病变;3例患者复发的皮肤病变具有不同程度的FDG摄取,1例患者肺部转移。B组中6例皮肤淋巴瘤PET均有阳性病变,但2例患者皮损或皮下结节无FDG摄取。综合分析10例PET/CT显像阳性者,8例患者有皮肤红斑和皮下结节,其中2例皮肤病变未见FDG摄取,2例仅部分皮肤病变摄取FDG。10例分期及再分期的淋巴瘤中,与常规方法比较PET/CT使2例(20%)分期上调。结论 FDGPET/CT对皮肤淋巴瘤的诊治有一定的临床价值。     

Giant cell arteritis on 18F‐FDG PET/CT

Purpose: We present a case of incidentally noted giant cell arteritis in a patient undergoing 18F‐fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT imaging. The patient was originally referred to PET/CT for staging of his renal transitional cell carcinoma. Methods: The patient was injected intravenously with 370 MBq of 18F‐FDG. After a 60 min uptake period, PET/CT imaging was performed from the skull base to the mid thighs. Results: A small para‐aortic node in the region of the surgical bed showed increased tracer uptake of concern for malignancy. In addition, there were several non‐calcified pulmonary nodules present, also concerning for malignancy. Incidentally noted was diffusely increased tracer uptake throughout the aorta and a thickened aortic wall on CT images. Diffuse tracer uptake was also present in the proximal branches of the aorta, including the carotid, iliac, femoral, and subclavian arteries. The patient had biopsy proven giant cell arteritis. Conclusion: Increased 18F‐FDG uptake by the aorta on PET/CT imaging is an abnormal finding that prompts a more thorough assessment for malignancy, and also can indentify important co‐morbidities in cancer patients. Evaluation of aortic uptake should be a routine practice in the interpretation of 18F‐FDG PET/CT scans.     

Patterns of FDG uptake in pancreatic non-Hodgkin’s lymphoma lesions

Purpose: The aim of this study was to evaluate the pattern of FDG uptake in pancreatic non-Hodgkin’s lymphoma (NHL) lesions. Methods: The study included 9 consecutive patients with newly diagnosed NHL with pancreatic involvement who underwent an F-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) scan. The location, size, maximal standardized uptake value (SUV_max), and FDG uptake patterns of the pancreatic lesions were reviewed. Results: Four different patterns of FDG uptake could be distinguished in the affected pancreas corresponding to different types of lymphoma lesions. These included focal FDG uptake by distinct solitary lesions (5 patients), multiple foci of FDG uptake corresponding to separate lymphoma lesions (1 patient), segmental FDG uptake caused by lymphoma infiltration limited to a pancreatic segment (1 patient), and diffuse FDG uptake related to diffuse lymphomatous infiltration of the entire pancreas (2 patients). All types of lesions showed increased metabolic activity with maximal standardized uptake values (SUVmax) ranging from 7.4 to 26.5. On CT images, the segmental and diffuse patterns of FDG uptake correlated to segmental and diffuse pancreatic enlargement accordingly. All lesions showed isodensity or slight hypodensity in relation to pancreatic tissue. The pancreatic head was the most frequent site of involvement (8/9). Mildly dilated pancreatic duct was noted only in 2 patients. Conclusions: The described patterns of FDG uptake and correlative CT findings may be helpful for a better characterization of NHL involving the pancreas and for differential diagnosis with other lesions, including pancreatic adenocarcinomas.     

急性白血病髓外复发的18F-FDG PET/CT特点

目的 探讨急性白血病（AL）髓外复发的¹⁸F-FDG PET/CT影像特点。方法 回顾分析30例AL髓外复发患者的PET/CT,观察髓外受累的器官或组织类型、最大标准化摄取值（SUV_max）及骨髓FDG摄取,比较急性淋巴细胞白血病（ALL）和急性髓系白血病（AML）的差异。结果 16例ALL累及45个髓外器官或组织,14例AML累及29个髓外器官或组织;前者髓外病灶的平均SUV_max为7.38±4.46,高于后者的4.87±2.66（t=3.022,P=0.003）。ALL患者累及淋巴结及软组织的病例数均为10例,平均SUV_max分别为6.38±3.55和10.12±5.48;AML患者累及淋巴结及软组织的病例数均为6例,平均SUV_max分别为4.82±1.43和6.60±4.58（P均>0.05）。5例ALL髓内复发者骨髓均为多灶性摄取,5例AML髓内复发者3例为弥漫性摄取,2例为多灶性摄取。结论 AL髓外复发的¹⁸F-FDG PET/CT影像表现有一定特点;ALL及AML的常见髓外复发部位均为淋巴结和软组织;ALL复发病灶FDG代谢活性较高;骨髓多灶性摄取对髓内复发有提示意义。